Guillain-Barre Syndrome due to Adjuvant Therapy with Dabrafenib Plus Trametinib
Open Access
- 4 April 2024
- journal article
- letter
- Published by Galenos Yayinevi in Balkan Medical Journal
- Vol. 41 (4) , 312-313
Abstract
No abstract availableThis publication has 11 references indexed in Scilit:
- Guillain-Barre Syndrome Secondary to the Use of Dabrafenib and Trametinib for the Treatment of Advanced Thyroid CarcinomaCureus, 2023
- Systemic adjuvant therapy for high-risk cutaneous melanomaTherapeutic Advances in Medical Oncology, 2022
- Guillain‐Barré Syndrome‐Like Polyneuropathy Associated with Immune Checkpoint Inhibitors: A Systematic Review of 33 CasesBioMed Research International, 2021
- Safety of BRAF+MEK Inhibitor Combinations: Severe Adverse Event EvaluationCancers, 2020
- The electrodiagnosis of Guillain-Barré syndrome subtypes: Where do we stand?Clinical Neurophysiology, 2018
- Acute motor and sensory axonal neuropathy related to treatment with MEK inhibitors in a patient with advanced melanomaMelanoma Research, 2017
- Adjuvant Dabrafenib plus Trametinib in Stage IIIBRAF-Mutated MelanomaNew England Journal of Medicine, 2017
- Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in MelanomaNew England Journal of Medicine, 2014
- Identification of Gene Networks and Pathways Associated with Guillain-Barré SyndromePLOS ONE, 2012